Atara Biotherapeutics
ATRA
Market cap $44.1M

7.78 USD

-0.03

0.38%

At close Oct 10, 4:00 PM EDT

1 day

-0.38%

5 days

5.85%

1 month

-9.43%

3 months

-13.75%

6 months

-56.63%

Year to date

-35.17%

1 year

-82.11%

5 years

-97.65%

About: Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Employees: 165

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

296% more call options, than puts

Call options by funds: $265K | Put options by funds: $67K

25.16% less ownership

Funds ownership: 83.04% [Q1] → 57.88% (-25.16%) [Q2]

43% less funds holding

Funds holding: 82 [Q1] → 47 (-35) [Q2]

59% less capital invested

Capital invested by funds: $58.8M [Q1] → $24.1M (-$34.7M) [Q2]

74% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 47

97% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 33

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

41%

upside

Avg. target

$14

80%

upside

High target

$18

131%

upside

3 analyst ratings

2 positive

67%

0 neutral

0%

1 negative

33%

Mizuho Salim Syed 44% 1-year accuracy 8 / 18 met price target	131%upside $18	Outperform Upgraded	16 Aug 2024
Canaccord Genuity John Newman 35% 1-year accuracy 6 / 17 met price target	67%upside $13	Buy Maintained	13 Aug 2024
Goldman Sachs Tommie Reerink 0 / 0 met price target	41%upside $11	Sell Maintained	17 Jul 2024

See Analyst Rankings

Financial journalist opinion

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,500 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,700 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 6:3.

Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into definitive agreements for the issuance and sale of 758,900 shares of its common stock at a purchase price of $8.25 per share and the issuance and sale of pre-funded warrants to purc.

Atara Biotherapeutics Announces $36 Million Registered Direct Offering

Zacks Investment Research

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $3.10 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to loss of $17 per share a year ago.

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2024, recent business highlights, and key upcoming milestones for 2024. “Building on the recent BLA acceptance with Priority Review for tab-cel, we are making signifi.

Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate at the Canaccord Genuity 44th Annual.

Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and pediatric.

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Zacks Investment Research

All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy

Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 2,200 restricted stock units of Atara's common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara's Board of Directors and granted under the Atara.

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

See News Rankings

Charts implemented using Lightweight Charts™